Cancer Biomarkers Market Research, 2027
The cancer biomarkers market size was valued at $10,944.08 million in 2019, and is projected to reach $26,979.50 million by 2027, registering a CAGR of 11.8% from 2020 to 2027. Cancer biomarkers are traceable substances or molecules that indicate the existence of cancerous cells in the body. The prevention of cancer by diagnosing and analyzing various cancer biomarkers using different diagnostic techniques is a profound approach to obtain rapid results for treatment. There are various types of biomarkers such as proteins, peptides, antibodies, and nucleic acids. Presence of these biomarkers in tissues, urine, serum, blood, and other body fluids indicate an abnormal process or a disease. Various such biomarkers for cancer indications have been studied and are used as biomarkers for diagnostics, prognostics, personalized medicine, and surrogate endpoints. The identification of different types of biomarkers is an integral part of various industries such as healthcare and pharmaceuticals.
The global cancer biomarkers market is expected to witness a significant growth during the forecast period due to increase in prevalence of various types of cancers such as breast, prostate, and lung cancer. In addition, surge in importance of biological & targeted drug therapies, technological advancements, accuracy, and reliability of cancer biomarkers also contribute toward the growth of the market. Moreover, increase in investments from governments and public & private sector toward R&D for cancer diagnostics have a positive impact on the market. However, high cost of drug development, threat of failure associated with cancer treatment, and unregulated government regulations and reimbursement policies hamper the cancer biomarkers market growth. In contrast, advancements of cancer research and significant unmet need for cancer diagnosis are anticipated to provide new opportunities for the cancer biomarkers market.
Global Cancer Biomarkers Market Segmentation
The market is segmented on the basis of profiling technology, biomolecule, cancer type, application, and region. By profiling technology, it is classified into omic technologies, imaging technologies, immunoassays, and cytogenetics-based tests. On the basis of biomolecule, it is segmented into genetic biomarkers, protein biomarkers, and glyco-biomarkers. By cancer type, it is categorized into breast cancer, lung cancer, prostate cancer, colorectal cancer, stomach cancer, and others. By application, it is segmented across diagnostics, drug discovery and development, prognostics, risk assessment, and others. Region-wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Profiling Technology Segment Review
By profiling technology, omic technologies and imaging technologies segments collectively accounted for 79.5% of the total market share in 2019, and is expected to exhibit a prominent growth rate in the future, owing to its efficiency in early diagnosis of cancer. In addition, demand for safe and cost-effective drugs for treatment of cancer, developments in profiling technology, growth in healthcare expenditure, reduced cost in genome sequencing, and demand for effective diagnostics & therapeutic procedures for cancer are expected to further fuel the market growth.
Biomolecule Segment Review
By biomolecule, the genetic biomarkers segment dominated the cancer biomarkers market in 2019, and is anticipated to maintain its dominance during the forecast period. This is attributed to its accuracy to predict the stage of cancer, detect recurrence of cancers, and monitor effectiveness of treatments. In addition, biomarkers can be assayed in non-invasively collected biofluids like blood or serum and it facilitates faster cancer diagnosis and early detection and screening of cancer. Moreover, cancer biomarkers, being subjected to dynamic modulation, can be used to enhance the understanding of efficacy, drug metabolism, drug action, and safety.
By Profiling Technology
Omic Technologies segment holds a dominant position in 2019 and would continue to maintain the lead over the forecast period.
Cancer Type Segment Review
By cancer type, lung cancer dominated the cancer biomarkers market in 2019, and is anticipated to maintain its dominance during the forecast period. This is attributed to high incidences of lung cancer. However, the breast cancer segment is anticipated to grow at the fastest CAGR of 16.70% during the forecast period. This can be attributed to the increase in prevalence of breast cancer due to the adoption of unhealthy lifestyle, genetic profile of patients, growth in female geriatric population, and exposure to harmful radiations.
Application Segment Review
By application, the prognostics segment dominated the cancer biomarkers market in 2019, and is anticipated to maintain its dominance during the forecast period. This is attributed to its application in estimating the stage and severity of a cancer. However, the diagnostics segment is anticipated to grow at the fastest CAGR of 12.00%during the forecast period. Surge in incidences of cancer globally facilitates the demand for biomarkers, which leads to the growth of the cancer biomarkers market.
By Application
Diagnostics segment is projected as one of the most lucrative segment.
North America accounted for majority of the market share in 2019, and is anticipated to continue this trend during the forecast period. This is attributed to the increased adoption of cancer biomarkers in the region. Moreover, high incidence rate of cancer in the region propels the market growth. In addition, various cancer biomarker diagnostics are covered under health insurance in the region. However, Asia-Pacific is anticipated to grow at the fastest rate during the forecast period, owing to increase in incidence rate of cancer in China and Japan. Moreover, rise in awareness and affordability for advanced cancer treatments further drives the Asia-Pacific cancer biomarkers market.
By Region
Asia-Pacific region would exhibit the highest CAGR of 15.1% during 2019-2026.
Comprehensive competitive analysis and profiles of major market players such as, Abbott Laboratories, Bio-Rad Laboratories, Inc., Bristol-Myers Squibb Company, Exact Sciences Corporation, F.Hoffmann-La Roche Ltd., Merck KGaA, PerkinElmer, Inc., Qiagen N.V., Siemens AG, and Thermo Fisher Scientific, Inc. are provided in this report.
Key Benefits For Stakeholders
- The cancer biomarkers market share and analysis is based on a comprehensive analysis of key developments in the cancer biomarkers industry.
- The development strategies adopted by the key cancer biomarkers market players are enlisted to understand the competitive scenario of the global market.
- The study provides an in-depth analysis of the cancer biomarkers market trends to elucidate the imminent investment pockets.
- The global market trends are studied from 2019 to 2027.
- Information about key drivers, restrains, and opportunities and their impact analysis on the cancer biomarkers market size is provided.
- Porter’s five forces analysis illustrates the potency of buyers and suppliers operating in the industry.
- The quantitative analysis of the market from 2020 to 2027 is provided to determine the market potential.
Key Market Segments
By Profiling Technology
- Omic Technologies
- Imaging Technologies
- Immunoassays
- Cytogenetics-based Tests
By Biomolecule
- Genetic Biomarkers
- Protein Biomarkers
- Glyco-biomarkers
By Cancer Type
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Stomach Cancer
- Others
By Application
- Diagnostics
- Drug Discovery and Development
- Prognostics
- Risk Assessment
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- United Arab Emirates
- Rest of LAMEA
Cancer Biomarkers Market Report Highlights
| Aspects | Details |
 By PROFILING TECHNOLOGY79 |
|
 By BIOMOLECULE124 |
|
 By CANCER TYPE |
|
 By APPLICATION |
|
 By Region |
|
 Key Market Players | BIO-RAD LABORATORIES, INC, QIAGEN N.V., Siemens AG, Abbott Laboratories, F. HOFFMANN-LA ROCHE LTD, Bristol-Myers Squibb Company, THERMO FISHER SCIENTIFIC, INC, EXACT SCIENCES CORPORATION, PERKINELMER, INC., Merck KGaA |
Analyst Review
Global cancer biomarkers market has witnessed huge technological innovations during the last decade, owing to high level of growth due to the rise in interest of physicians towards early detection of cancer. Detection of cancer using biomarkers is on a continuous rise at a high rate and is expected to dominate the cancer diagnostics market during the forecast period. Use of cancer detection techniques using biomarkers coupled with growth in number of cancer population supplements the growth of the cancer biomarkers market.
Currently, cancer detection using biomarkers is dominant in developed regions owing to the high healthcare expenditure and favorable reimbursement policies. However, the demand for novel cancer biomarkers is expected to shift from developed regions to developing regions due to rise in healthcare expenditure and growth in awareness about cancer. Furthermore, regulatory support from the respective government authorities and active initiatives from leading companies to create awareness for cancer diagnosis are further expected to boost the market growth during the forecast period.
The total market value of cancer biomarkers market is $10,944.08 million in 2019.
The market value of cancer biomarkers market in 2019 is $12,383.23 million.
The base year is 2019 in cancer biomarkers market
Top companies such as, F. Hoffman-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Qiagen NV, and Bristol-Myers Squibb Company held a high market position in 2019. These key players held a high market postion owing to the strong geographical foothold in different regions.
Profiling technology segment is the most influencing segment owing to factors such as increase in popularity due to the growing role of precision and personalized medicine for cancer treatment and growth in healthcare expenditure. In addition, increase in prevalance of cancer also has increased the demand for advancement of the profiling technology. Hence, this is most influencing segment growing in cancer biomarkers market.
The major factor that fuels the growth of the global cancer biomarkers market includes rise in prevalence of cancer. This leads to surge in demand for cancer biomarkers which contribute to the growth of the market.
Asia-Pacific has the highest growth rate in the market which is growing due to the contribution of the following emerging countries such as India with a CAGR of 15.1%. This is due to improvement in health awareness, development in healthcare infrastructure, and rise in number of hospitals & diagnostic centers equipped with advanced medical facilities.
Cancer biomarkers refers to a substance or specific response of the body that can either be molecules that are secreted by tumor cells or processes that indicate the presence of cancer in the human body.
The cancer biomarkers are used in several applications including diagnostics, drug discovery and development, prognostics, risk assessment, and others. Several profiling technology and biomolecules are utilized to collect patient information to obtain accurate results that are used to treat and diagnose cancer.
Loading Table Of Content...
